The inhaled booster is the first approved alternative to an injectable COVID-19 vaccine.
, or fear of needles. Regulators in China have approved a COVID-19 vaccine booster nasal spray, providing those virus-fighting antibodies without the jab of a needle., one breath of their vaccine mist provides protection against COVID-19. The dose will be used as a booster and is the first approved alternative to injectable COVID-19 vaccines.
. “It’s just a bit trickier than testing first-generation intramuscular vaccines in an infection-naive population,” he added.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Media critics not buying 'startling' Biden White House efforts to blame Trump for COVID school woesThe Biden administration is using 'revisionist history' to cast blame on former President Trump for harmful COVID-era school closures, media critics say.
Lire la suite »
Life Expectancy in the U.S. Just Had a Historic DropLife Expectancy in the U.S. Just Had a Historic Drop—Again
Lire la suite »
Long Covid is keeping millions out of work, Brookings report finds - Phoenix Business JournalLong Covid is proving to have a substantial effect on the workforce, according to new research. Experts say employers can't ignore the issue.
Lire la suite »
COVID-19 took a unique toll on undocumented immigrantsThe pandemic compounded barriers to accessing medical care—and many continue to delay or forgo treatment.
Lire la suite »
'No man's land': Long COVID knocks young workers out of the job market'This is a $3.5 trillion problem,' one economics professor tells ABC News. 'And there are very few 3.5 trillion problems that we know as little as we know about this.' Read more, via AnneKFlaherty:
Lire la suite »
Powerful New Antibody Neutralizes All Known COVID VariantsFuture vaccine development may be inspired by the findings. Therapeutic antibodies that were effective early in the pandemic have lost their efficacy as SARS-CoV-2 has changed and mutated, and more recent variants, particularly Omicron, have learned how to circumvent the antibodies our systems prod
Lire la suite »